This week the money in medical AI went around the models entirely and bought distribution instead. The VA's five-year, $775.72M enterprise vehicle awarded on Sep 22 is a ceiling, not a cheque: Abridge won a seat and must still win task orders from 170 medical centres, alongside Knowtex. On Sep 29 Oura pulled a $2.2B IPO — 55 million shares at $40–44 — leaving a roughly $15B valuation outside the door while holding 5.7 million paying subscribers and $907.9M of prior-year revenue. And in the same week private capital repriced three companies on ARR multiples: OpenEvidence at $250M/$15B, EliseAI at $350M/$4B on $200M+ ARR, and Heidi at $340M/$900M on ARR that went from $1M to $50M in two years.
What is worth remembering about this week is not any new model but where the money went: around the models entirely, to buy who is already using something. The largest distribution event came from government — on September 22 the VA put ambient clinical AI onto a five-year, multi-vendor enterprise vehicle with a $775.72 million ceiling, and Abridge won a seat. But The Inference takes it apart and concludes it is a ceiling, not a cheque: converting it means winning task orders from 170 medical centres one at a time. The exit closed in the same week: on September 29 Oura pulled its entire Nasdaq IPO of 55 million shares at $40–44, up to $2.2 billion (TechCrunch), while Rock Health counted zero digital health IPOs in the first half of 2026, $7.4 billion spread across 244 deals, and 45% of all capital absorbed by 20 mega-deals (Healthcare Dive). So price discovery moved wholesale into private markets — three rounds in one week: OpenEvidence at $250M/$15B (Forbes), EliseAI at $350M/$4B (release) and Heidi at $340M/$900M (Fierce Healthcare), $940 million in all. Then on October 5 HHS opened four AI clinical-trial programmes through ARPA-H (Nextgov/FCW), also priced as ceilings. The question this issue asks is simple: when distribution costs more than the model, who actually got paid.
01 — Top Stories
A $775.72M VA enterprise vehicle is a spending ceiling, not a cheque
On September 22 the Department of Veterans Affairs put ambient clinical AI onto a five-year, multi-vendor enterprise vehicle with a $775.72 million spending ceiling, and Abridge took one of the seats (Nextgov/FCW, company release). The structure is the story: The Inference takes the award apart and points out the figure is the ceiling on the whole vehicle rather than guaranteed revenue, Abridge's own share is undisclosed, and converting it into payments means winning task orders from 170 medical centres one at a time. The pilot that began in October 2025 has now reached more than 75 medical centres across primary care, behavioural health, rehabilitation and surgical specialties, and every note still requires physician approval before it enters a veteran's record. Knowtex, a fellow October 2025 pilot vendor, holds a seat on the same vehicle.
This is the quarter's largest single distribution event in medical AI, and it demonstrates the real shape of government-as-buyer: the ceiling makes the headline, the task orders make the revenue. The cautionary case sits next door — Oracle's EHR contract ceiling was raised to $27 billion in August 2026, which drew congressional subpoenas and testimony expected before year-end (The Inference). A ceiling reported as a revenue expectation ends up costing trust. Abridge says it will support over 100 million patient conversations across 300-plus health systems in 2026, and its June 2025 Series E valued it at $5.3 billion — up 524% from $850 million in February 2024 — with no realised figure yet attached to this VA award.
The $775.72M is the ceiling on a multi-vendor vehicle, not Abridge's contract value; the 100-million-conversation and 300-health-system figures are company-reported and not independently audited.
Oura pulled a $2.2B IPO outright — not for want of demand, but of price
Smart-ring maker Oura postponed its Nasdaq listing indefinitely on September 29. The deal was 55 million shares at $40–44, raising up to $2.2 billion, implying roughly a $15 billion valuation at the midpoint (TechCrunch, CNBC). The business is not the problem: 5.7 million paying subscribers, up from 5 million in June; $907.9 million of prior-year revenue with 90% growth projected for 2026; 89% gross margin on membership revenue; $372 million of cash as of June. The proceeds were earmarked largely to cover employee tax obligations on vesting share grants rather than operations. Early backer Forerunner Ventures, holding 9.3%, was set to sell its entire stake for around $1.2 billion. CEO Tom Hale said the company has "the luxury of choosing our moment".
This is the clearest exit signal in health tech this year. Rock Health counted zero digital health IPOs in the first half of 2026, with Oura the company closest to filing (Healthcare Dive). A company with nearly a billion dollars of revenue, 89% gross margin and still-growing subscriptions declining to list at this price pushes price discovery back into the private market entirely — which is exactly what the other three mega-rounds of the same week look like. There is a more practical implication too: when an IPO is the mechanism for settling employees' vesting tax bills, postponing it keeps the liquidity pressure inside the company.
The 90% growth figure is the company's own projection, not a reported result; the ~$15B valuation is derived from the midpoint of the price range, not a clearing price.
OpenEvidence confirms $250M at a $15B valuation — and the product is still free to US physicians
On September 30 founder Daniel Nadler confirmed OpenEvidence had raised another $250 million at a $15 billion valuation (Forbes); Axios Pro had reported the round, with a16z participating, on September 25. The company's clinical decision support tool is free to US physicians, and a partnership with Anthropic is taking it into nearly 100 countries at no cost, tuned to local clinical guidelines, with the emphasis on Africa and Asia. Its direct competitors are UpToDate, the legacy incumbent now shipping AI features, and Doximity, with more than three million healthcare users.
A $15 billion valuation attached to a product that is free to its users means investors are not buying subscription revenue; they are buying share of physician attention and the option to monetise later — the exact inverse of the ARR-multiple logic applied to EliseAI and Heidi in the same week. Worth noting: Dealroom's write-up flags the round as accompanying a move toward oncology drug development. If that holds, the revenue scale on that path is in a different order of magnitude from clinical search, and it explains how free distribution can carry this price.
The oncology-development angle appears only in secondary coverage and deal-database write-ups, with no formal company announcement; the investor list beyond a16z is incomplete, and no revenue or user figures were disclosed.
EliseAI's $350M Series F at $4B: a valuation doubled in 13 months, on a disclosed ARR
On September 29 EliseAI announced a $350 million Series F at a $4 billion valuation, co-led by Andreessen Horowitz and Bessemer Venture Partners, with Ontario Teachers' Pension Plan, Sapphire Ventures and Navitas Capital participating (GlobeNewswire release, Fierce Healthcare fundraising tracker). The company applies AI to operational automation across both healthcare and housing, and disclosed that ARR passed $200 million in June, having doubled year over year for five consecutive years.
Among three mega-rounds in one week, EliseAI is the only company to put a valuation and an ARR on the table at once: $4 billion against $200 million, roughly 20x. That multiple is now the private market's reference point, and the only external anchor for judging the valuations of companies that disclose no ARR at all — Abridge and OpenEvidence among them. The second industry signal is cross-vertical reach: the same voice and messaging automation sells into healthcare and housing alike, which says the real asset in this generation of companies is the wiring into operational workflow, not a healthcare-specific model.
The $200M ARR and the five-year doubling are company-reported and unaudited; the revenue split between healthcare and housing is not disclosed.
Heidi raises $340M at $900M: ARR from $1M to $50M in two years, and a declared move beyond documentation
Heidi's $340 million came in two parts: a $100 million Series C led by Blackbird with Phoenix Court, Point72 Private Investments and Headline, plus a $240 million growth investment led by General Catalyst's Customer Value Fund. The Series C valued the company at $900 million, double the $465 million of October 2025 (Fierce Healthcare, Digital Health Wire). The operating numbers are unusually specific: ARR from $1 million to $50 million in two years; 2.8 million patient interactions a week across 110 languages and 190 countries; 175 million patient visits supported, up from 73 million at the Series B, and over 67 million clinical hours, tripled since September 2025; and more than 10 million evidence queries answered since the Evidence tool launched in March 2026. Deployments span Australia, New Zealand, the UK — where it is sole supplier to NHS England Midlands — and the US, with a system-wide rollout at Beth Israel Lahey Health, plus an R1 RCM integration.
Heidi is the clearest bottom-up case in the ambient layer: no single federal award, but individual clinician adoption across 190 countries growing upward into system-level contracts and NHS exclusivity. Set against Abridge's path — large US health systems plus a federal vehicle, high contract value, long sales cycles, undisclosed ARR — the two routes each took money in the same week, and only one of them put its ARR on the table. The move worth watching is "beyond documentation": going from scribe to agentic work and clinical decision support walks straight into OpenEvidence's territory, and adding the Remote wearable means fighting on three fronts at once.
ARR, interaction counts, clinical hours and query volumes are all company-reported; the $240M growth tranche comes through General Catalyst's Customer Value Fund, which is structurally different from ordinary equity.
On Oct 5 HHS opened four AI clinical-trial programmes; Evidence Health leads two, worth up to $91.08M combined
The Department of Health and Human Services announced four programmes through ARPA-H on October 5 (Nextgov/FCW). The anchor programme, SURPASS, seeks AI-powered platforms for adaptive trial design across three technical areas — phaseless design engines, continuous inference engines, and agentic AI operations layers — with solution summaries due November 30. Three others already have leads: STACK, led by Evidence Health for up to $41.18 million, uses AI to activate trial sites and convert research-naive facilities into enrolling ones, partnering with UT Austin's Dell Medical School; COMMONS, also led by Evidence Health for up to $49.9 million, builds national data infrastructure targeting 40-plus million individuals and three million linked records, including consent architecture and regulatory-grade data access; and CINCH, led by Courage Health for up to $8.95 million, lets cancer patients contribute their own data for trial matching. These follow Operation TrialBlazer in June 2026 and the FDA's April 2026 AI monitoring pilot, which estimated a potential 40% reduction in overall trial timelines.
This is the second piece of evidence for the week's through-line: the industry's largest new buyer is government, and government money also arrives as a ceiling. HHS's own framing is that drug development typically takes more than a decade, costs up to $2 billion and fails over 90% of the time — meaning what these awards are really buying is trial cycle time, not model accuracy. The concentration is notable: in one batch of announcements a single company, Evidence Health, leads two of the programmes and over 90% of the committed ceiling. That is the same shape as mega-deals absorbing most of the private capital.
All four figures are ceilings ("up to"), not disbursed amounts; SURPASS is still at solicitation stage with no awardee; the 40% timeline reduction is an estimate from the FDA pilot, not a measured result.
A 25-person, VC-free AI agent team gets bought by the channel: DexCare acquires Mila Health
Seattle-based DexCare announced on September 21 that it had acquired neighbouring Mila Health for undisclosed terms (GeekWire, Health IT Answers). DexCare handles patient scheduling, referrals and insurance information, reaching 57 million patients nationwide through customers including Kaiser Permanente, Piedmont, Texas Health Resources and Tampa General; it has raised $146 million, most recently $75 million in 2023, with roughly 133 employees. Mila Health builds AI agents that automate scheduling-related patient communication over calls and texts; it launched in January 2024, has 25 employees and no venture funding. Co-founder and CEO Shailu Verma was previously Chief Product Officer at UnitedHealth Group and before that a product manager at AWS. Verma's framing: "Healthcare systems need auditable AI agents configured for specific tasks." DexCare CEO Matt Blosl located the difficulty in "building infrastructure and managing agent boundaries".
This is the week's only real acquisition, and its direction describes the reality of the agent layer: the technology is cheap, the channel is expensive. Mila built working voice and text agents in two years without venture money, and the way that value got realised was by plugging into a platform that already holds 57 million patients and customers like Kaiser. Rock Health counted 115 acquisitions in the first half of 2026, pacing ahead of 2025's 199 for the full year (Healthcare Dive) — in a half-year with zero IPOs, M&A is the actual exit.
Terms are undisclosed, so no multiple can be inferred; the 57-million figure is DexCare's reported reach, not active usage.
02 — Product Analysis
Abridge
Ambient clinical documentation · Abridge AI (US)
Function and position. Turns the clinical conversation into structured documentation in real time, sold to large health systems and federal agencies, with every note requiring physician approval before it enters the record (Nextgov/FCW). It has been piloting at the VA since October 2025 and now covers more than 75 medical centres across primary care, behavioural health, rehabilitation and surgical specialties; its June 2025 Series E valued it at $5.3 billion (The Inference).
- Strength : once inside a federal enterprise vehicle, task orders from 170 medical centres are structural repeat business and hard for a competitor to interrupt — only Abridge and Knowtex hold seats on this $775.72M vehicle (Nextgov/FCW).
- Concern : there is no public ARR next to the $5.3 billion. Two of this week's three private rounds disclosed theirs — EliseAI at $200M, Heidi at $50M — Abridge did not, and its headline number is an "up to". The Inference uses Oracle's raised $27 billion EHR ceiling and the congressional subpoenas that followed as the cautionary case: a ceiling talked about as revenue costs trust.
Heidi
Ambient documentation → clinical AI partner · Heidi (Australia)
Function and position. Starting from an AI scribe and extending into agentic tasks, clinical decision support (Evidence), a wearable (Remote) and dictation (Dictate), it handles 2.8 million patient interactions a week across 110 languages and 190 countries; it is sole supplier to NHS England Midlands, with a system-wide US rollout at Beth Israel Lahey Health (Fierce Healthcare).
- Strength : ARR went from $1 million to $50 million in two years, and it is disclosed; 175 million patient visits supported against 73 million at the Series B, and over 67 million clinical hours, tripled in a year (Fierce Healthcare, Digital Health Wire). Bottom-up adoption costs contract value but buys independence from any single award.
- Concern : fighting on scribe, clinical evidence and wearables at once, with the second front running straight into OpenEvidence at its fresh $15 billion valuation (Forbes). And the $240 million came through General Catalyst's Customer Value Fund, structurally unlike ordinary equity and not to be read as part of the $100 million Series C.
03 — Companies & Competition
| Company | Recent state & numbers | Position & moat |
|---|---|---|
| Abridge Ambient clinical documentation (US) |
Won a seat on the VA's five-year enterprise vehicle on Sep 22, $775.72M ceiling with its own share undisclosed; pilot now at 75+ medical centres; $5.3B valuation at the June 2025 Series E (The Inference, Nextgov). | The moat is procurement friction at federal and large-system level plus installed deployments; the thin spot is the absent public ARR, with the headline number being a spending ceiling. |
| Heidi Ambient → clinical AI partner (Australia) |
$340M ($100M Series C plus $240M growth) at a $900M valuation, double October 2025's $465M; ARR from $1M to $50M in two years; 2.8M interactions a week (Fierce Healthcare). | The moat is individual clinician adoption across 190 countries plus NHS Midlands exclusivity; the thin spot is three product fronts at once, one of them facing OpenEvidence. |
| OpenEvidence Clinical decision support / evidence search (US) |
Confirmed $250M at a $15B valuation on Sep 30 with a16z participating (Forbes, Axios Pro); free to US physicians, going into nearly 100 countries with Anthropic. | The moat is physician habit and the coverage speed that free distribution buys; the thin spot is no subscription revenue to anchor on, against UpToDate's channel and Doximity's three million healthcare users. |
| EliseAI Healthcare and housing operations automation (US) |
Closed a $350M Series F at $4B on Sep 29, co-led by a16z and Bessemer; ARR passed $200M in June, doubling for five consecutive years (release). | The moat is cross-vertical workflow wiring at scale with a real ARR behind it; the thin spot is an undisclosed split between healthcare and housing, leaving the healthcare half's true thickness unknown. |
| Oura Consumer health wearable / subscription (Finland) |
Postponed its Nasdaq IPO indefinitely on Sep 29 (55M shares at $40–44, up to $2.2B); 5.7M paying subscribers, $907.9M prior-year revenue, 89% membership gross margin, $372M cash in June (TechCrunch). | The moat is subscription margin and device stickiness; the thin spot is liquidity — the IPO was meant to settle employees' vesting taxes, so postponing keeps that pressure inside. |
| DexCare Patient access and scheduling platform (US) |
Acquired Mila Health — 25 people, no VC funding — on Sep 21 for undisclosed terms; reaches 57M patients with customers including Kaiser Permanente and Texas Health Resources, having raised $146M (GeekWire). | The moat is scheduling and referral pipes already wired into health systems; the thin spot is that agent technology is cheap, and what it bought a rival can buy too. |
| Evidence Health AI clinical trial infrastructure (US) |
Leads two of the programmes in ARPA-H's Oct 5 batch: STACK at up to $41.18M and COMMONS at up to $49.9M, the latter targeting 40M+ individuals and three million linked records (Nextgov/FCW). | The moat is a position in government data infrastructure plus consent and regulatory-grade access architecture; the thin spot is that both figures are ceilings and the customer base is one federal buyer. |
Today's competitive structure is a funnel, and its narrow end is not the model. Of seven companies, the largest numbers — Abridge's $775.72M, Evidence Health's $91.08M — are ceilings rather than receipts. The two that put ARR on the table, EliseAI at $200M and Heidi at $50M, are valued at $4B and $900M, roughly 20x and 18x. The most valuable, OpenEvidence at $15B, has no subscription revenue to take a multiple on. And the week's only acquisition bought 25 people and a set of pipes (GeekWire). Put plainly: the market is paying its highest prices for two things — distribution already wired in, or ARR already verifiable. Whoever had neither did not get funded this week.
04 — Taiwan Angle
(1) Chihjet, on October 5, is selling algorithm licences rather than ARR. Chihjet Medical Technology, chaired by Sun Jixun, is built on its Anatomy Cloud technology: converting conventional 2D greyscale CT and MRI images into high-definition colour 3D models in three to five minutes, identifying over 260 organs and tissues, viewable in a browser, on mobile, or through a mixed-reality headset. It is in testing at the Ministry of Health and Welfare's data centre, aiming to reach all 29 of Taiwan's medical centres by 2028. The company has also completed an acquisition of the Japanese medical imaging firm Holoeyes, plugging into a network of more than 100 Japanese hospitals, with revenue planned through algorithm licensing, equipment leasing and co-developed surgical robotics (Newtalk). Against this week's three US rounds — priced on ARR multiples or share of attention — Taiwan's route is hardware plus licensing, a completely different cash-flow structure, so a 20x-ARR frame does not read it correctly.
(2) The structure of the VA award is worth reading word by word in Taiwan. A five-year, multi-vendor vehicle priced as a spending ceiling and converted only through task orders issued hospital by hospital (The Inference) closely resembles how tenders work between the Ministry of Health and Welfare and individual medical centres: winning a place grants eligibility, while revenue depends on what each hospital actually buys. Chihjet's "29 medical centres by 2028" is the same grammatical form — it describes eligibility and intent, not contracted value. That distinction is worth keeping on separate ledgers, externally and internally.
(3) A shut IPO window lands harder on Taiwanese medical AI, where listing is the main exit. Oura, with 5.7 million paying subscribers, $907.9 million of prior-year revenue and 89% membership gross margin, still chose not to list at roughly a $15 billion valuation (TechCrunch); and Rock Health counted zero digital health IPOs in the first half of 2026 against 115 acquisitions, pacing ahead of 2025's 199 for the year (Healthcare Dive). Chihjet is targeting an emerging-stock listing in 2027 (Newtalk), which falls inside that window; in a half-year where M&A is the exit, hardening revenue and customer counts is worth considerably more than hardening a valuation.
05 — Further Reading
-
Abridge's $775.72 million VA win is a ceiling, not a check — The Inference (2026-09)
The only piece this week that actually takes the contract structure apart: ceiling, seat, task orders, 170 medical centres, and the cautionary parallel of Oracle's $27B ceiling drawing subpoenas. If you read one thing on government-as-buyer, read this.
-
Large funding rounds help boost digital health investment in H1 — Healthcare Dive (2026-07-16)
Every claim about capital concentration here is anchored to these figures: $7.4B across 244 deals, a $14M median, 20 mega-deals taking 45% of capital, 115 acquisitions, zero IPOs. Read it for the denominator.
-
Oura shelves its $2.2B IPO, citing 'uncertainty' in the market — TechCrunch (2026-09-29)
Explains why a company with nearly a billion in revenue and 89% gross margin chose not to list, including the key detail that the proceeds were earmarked for employees' vesting taxes — the sentence that explains what postponement costs.
-
Heidi lands $340M to build 'AI care partner' for clinicians — Fierce Healthcare (2026-09)
The week's one funding story that gives the ARR curve, cumulative visits, clinical hours and query volume all at once. If you want a verifiable ARR multiple to check other valuations against, it is here.
-
HHS unveils efforts to speed up clinical trials with AI — Nextgov/FCW (2026-10-05)
Lays out the amounts, leads and technical areas for all four programmes, including the November 30 SURPASS deadline. If you are thinking about next year's government awards, this is a starting point rather than a news item.
06 — References
- Abridge's $775.72 million VA win is a ceiling, not a check. The Inference, 2026-09. theinference.org
- VA selects Abridge ambient scribe under new enterprise contract. Nextgov/FCW, 2026-09-22. nextgov.com
- Abridge Wins Seat on $775.7M VA Enterprise Contract to Power Ambient Clinical AI. HIT Consultant, 2026-09-22. hitconsultant.net
- Abridge Selected to Bring Ambient AI to Veteran Care Nationwide Through the VA Enterprise Contract. Business Wire / FinancialContent, 2026-09-22. financialcontent.com
- Abridge Wins VA Ambient AI Contract: Federal Scale Validated. Futurum Group, 2026-09. futurumgroup.com
- Oura shelves its $2.2B IPO, citing 'uncertainty' in the market. TechCrunch, 2026-09-29. techcrunch.com
- Smart ring maker Oura postpones IPO due to market 'uncertainty'. CNBC, 2026-09-29. cnbc.com
- OpenEvidence Confirms It Has Raised An Additional $250 Million At A $15 Billion Valuation. Forbes, 2026-09-30. forbes.com
- OpenEvidence reportedly raises $250M at $15B valuation. Axios Pro Health Tech Deals, 2026-09-25. axios.com
- OpenEvidence raises $250M at $15B valuation, quietly pivots to oncology drug development. Dealroom, 2026-09. dealroom.co
- EliseAI Raises $350 Million at $4 Billion Valuation to Bring AI Deeper Into Housing and Healthcare Operations. GlobeNewswire, 2026-09-29. globenewswire.com
- Fierce Healthcare Fundraising Tracker '26. Fierce Healthcare, 2026-09-29. fiercehealthcare.com
- Heidi lands $340M to build 'AI care partner' for clinicians. Fierce Healthcare, 2026-09. fiercehealthcare.com
- Heidi Closes Series C and Sets Sights on Clinical Work. Digital Health Wire, 2026-09. digitalhealthwire.com
- Heidi secures $340M to turn its NHS AI scribe into a full clinical AI partner. Tech Funding News, 2026-09. techfundingnews.com
- HHS unveils efforts to speed up clinical trials with AI. Nextgov/FCW, 2026-10-05. nextgov.com
- Seattle startups DexCare and Mila Health combine to expand AI patient scheduling. GeekWire, 2026-09-21. geekwire.com
- Health IT Business News, Financial Edition. Health IT Answers, 2026-10-01. healthitanswers.net
- Large funding rounds help boost digital health investment in H1. Healthcare Dive, 2026-07-16. healthcaredive.com
- H1 2026 funding and market overview: Durable roots, shifting routes. Rock Health, 2026-07. rockhealth.com
- 智捷：AI 3D醫療影像系統 拚2028年導入29家醫學中心. 新頭殼 Newtalk, 2026-10-05. newtalk.tw
- Angle Health snags $600M, hits $2.7B valuation. Fierce Healthcare, 2026-09-18. fiercehealthcare.com
- Medtronic Announces Strategic Partnership with Cornerstone Robotics. Medtronic Newsroom, 2026-09-01. news.medtronic.com
- Qualified Health raises $125 million, as it helps more health systems build and manage AI tools. STAT News, 2026-03-25. statnews.com
- Qualified Health locks in $125M in fresh funding to scale enterprise AI at health systems. Fierce Healthcare, 2026-03. fiercehealthcare.com